Portable Screening Test For Tuberculosis
A Key Requirement To Eradicate a Global Pandemic
Epilab's state of the art technology helps health organisation that want to fight tuberculosis by improving the rate of diagnosis in developing countries and reducing the number of new infections and victims.
Thank you to everyone who made this journey possible !
Epilab has closed down
December 2023
Even though a clinical study was validated with Cameroon authorities and scheduled for early 2023, the tuberculosis screening market has changed. Many of the technologies developed to screen for Covid have been redirected to tuberculosis screening, making Epilab technology significantly less competitive.
At the end of 2023, Epilab's intellectual property was therefore transferred to public laboratories and the company was liquidated.
If you are interested in our story, Epilab's cofounders Maurice and Clément appeared in the podcast "Lets fund out". From the beginning to the end, they share the journey of Epilab and what they have learned.
Links here : Spotify, Apple Podcast, YouTube, Deezer.
Tuberculosis In Figures
10 Million New Cases Each Year
Each year, 10 million people contract tuberculosis. One-third of these new cases, representing about 3 million individuals, are not detected and remain unknown to health organisations. As a result, patients are not receiving appropriate treatment, thereby allowing for ongoing disease transmission.
4 Million Undetected Cases
Eighty percents of new yearly cases emerge in developing countries that lack resources to implement successful diagnosis campaigns. Existing tests are not adapted to the needs of those countries.
4 in10 people with tuberculosis
are not diagnosed or treated
1.5 Million Victims
Despite being a preventable and curable disease, 1.5 million people die from tuberculosis each year because their diagnosis is “missed,” making it the world’s top infectious disease killer.
The main reason of this underdiagnosis are:
-
Infrastructure (labs) required : most of the population does not have easy access to the few existing infrastructures
-
Medically qualified staff required
-
Testing is expensive.
-
Available tests are unquantifiable and lack sensitivity
They Support Us
Get In Touch
NEWS
Rotary Club Impact Startup Award
May 2022
Epilab is honored to receive the Rotary Club Impact StartUp Award.
This price acknowledges project with a strong social impact while having technological and human dimensions.
Epilab at ChangeNOW
May 2022
Epilab had the opportunity present the solution for TB detection at ChangeNOW, the world’s largest event for the planet
Every year, it brings together the most innovative solutions and impactful changemakers tackling our planet’s biggest challenges, to take action, together. ChangeNOW builds bridges between the entrepreneurs, business leaders and policy-makers to accelerate change.
Interview with Epilab at France biotech
June 2021
France Biotech is the French trade association of biotechnology companies. Its primary mission is to support the development of this industry in France.
Epilab was the subject of the 5th episode of its "Pépites Healthtech" series where France Biotech present promising start-ups.
New scientific publication
September 2022
New publication in Talanta : "Rapid electrochemical detection of Mycobacterium tuberculosis in sputum by measuring Ag85 activity with disposable carbon sensors”.
This article presents the first data Epilab patented technology patients samples from Bichat Hospital. The results are very promising with a specificity of 78% and a sensitivity of 89%.
Thank you to everyone who made this journey possible !
Epilab has closed down
December 2023
Even though a clinical study was validated with Cameroon authorities and scheduled for early 2023, the tuberculosis screening market has changed. Many of the technologies developed to screen for Covid have been redirected to tuberculosis screening, making Epilab technology significantly less competitive.
At the end of 2023, Epilab's intellectual property was therefore transferred to public laboratories and the company was liquidated.
If you are interested in our story, Epilab's cofounders Maurice and Clément appeared in the podcast "Lets fund out". From the beginning to the end, they share the journey of Epilab and what they have learned.
Links here : Spotify, Apple Podcast, YouTube, Deezer.
December 2023
Prix Galien 2022
October 2022
Epilab is selected for the 2022 PrixGalienUSA in the category "Best Startup in the Medical Technology Industry".
It is an honor for us to be nominated for this award, which recognizes excellence in R&D that has significantly improved the human condition.
The awards ceremony was held on October 27, 2022, in NYC to celebrate the committed companies creating a healthier future for patients.
ABOUT US
EpiLAB is developing a portable screening test for tuberculosis, to diagnose the 3 million cases undetected each year, of the world’s top infectious killer.
CONTACT US
Work office : Drahi X Novation Center, 91120, Palaiseau
Registered office : 4 rue Anatole France, 78350, Jouy-en-Josas, France
